Company Analysis
Sign in

NuCana plc (NCNA)

Nasdaq: NCNA · Pharmaceutical Preparations · Edinburgh, GB · filing with the SEC since 2017
Full chart Alerts Compare
Grade5.0
◀ Past 4.3● Present 4.3▶ Future 6.1
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

33 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to NuCana plc’s names, not what it holds today.

Patents granted
33
32 utility, 1 reissue, 1976 to Dec 31, 2025
Granted in 2025
1
Against 4 in 2024 and 6 in 2023
Applications published
54
5 of them in 2025
Names they are printed under
4
its own name, a former name
By yearGrantedApplications published
'12'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals11
Organic fine chemistry9
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
NuCana plc its own name
GB, as the owner printed on each patent
28 granted
18 published
NuCana plc its own name
named as the applicant on its applications, in GB
0 granted
27 published
NuCana Biomed Limited a former name
named as the applicant on its applications, in GB
0 granted
8 published
NuCana BioMed Limited a former name
GB, as the owner printed on each patent
5 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 15, 202512,357,652Formulations of phosphoramidate derivatives of nucleoside drugsPharmaceuticalsNuCana plc
Aug 6, 202412,054,511Synthesis of phosphate derivativesOrganic fine chemistryNuCana plc
Aug 6, 202412,054,5102′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compoundsOrganic fine chemistryNuCana plc
Mar 12, 202411,925,658Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancerPharmaceuticalsNuCana plc
Feb 13, 202411,897,913Synthesis of 3′-deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)]phosphate (NUC-738)Organic fine chemistryNuCana plc
Oct 17, 202311,786,544Formulations of phosphoramidate derivatives of nucleoside drugsPharmaceuticalsNuCana plc
Jul 25, 202311,707,477Formulation comprising a gemcitabine-prodrugPharmaceuticalsNuCana plc
Apr 18, 202311,629,164Gemcitabine prodrugsPharmaceuticalsNuCana plc
Mar 14, 202311,603,382Diastereoselective synthesis of phosphate derivativesOrganic fine chemistryNuCana plc
Jan 24, 202311,560,400Salts of diphosphate phosphoramidate of nucleosides as anticancer compoundsPharmaceuticalsNuCana plc
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 2, 20252025/0302859FORMULATIONS OF PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE DRUGSPharmaceuticalsNuCana plc
Sep 25, 20252025/0296948SYNTHESIS OF NUCLEOSIDE DERIVATIVESOrganic fine chemistryNuCana plc
May 29, 20252025/0171487SYNTHESIS OF PHOSPHATE DERIVATIVESOrganic fine chemistryNuCana plc
May 22, 20252025/01630962' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDSOrganic fine chemistryNuCana plc
May 8, 20252025/0144128CANCER TREATMENTPharmaceuticalsNuCana plc
Sep 5, 20242024/0293439TREATMENT REGIMENSPharmaceuticalsNuCana plc
Mar 14, 20242024/0082287FORMULATIONS OF PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE DRUGSPharmaceuticalsNuCana plc · patent 12,357,652 granted from it
Jul 20, 20232023/0226092CANCER TREATMENTS BASED ON GEMCITABINE PRODRUGSPharmaceuticalsNuCana plc
Jul 13, 20232023/0218655CANCER TREATMENTSPharmaceuticalsNuCana plc
Jun 22, 20232023/0192750SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDSPharmaceuticalsNuCana plc
What it applied for, 2024 to 2025: Pharmaceuticals 4 · Organic fine chemistry 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton NCNA · research, not advice